STAA logo

STAAR Surgical Company Stock Price

NasdaqGM:STAA Community·US$1.3b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 8 Fair Values set on narratives written by author

STAA Share Price Performance

US$26.18
-5.01 (-16.06%)
6.5% undervalued intrinsic discount
US$28.00
Fair Value
US$26.18
-5.01 (-16.06%)
5.7% undervalued intrinsic discount
US$27.75
Fair Value
Price US$26.18
AnalystHighTarget US$27.75
AnalystConsensusTarget US$24.63
AnalystLowTarget US$15.25

STAA Community Narratives

AnalystHighTarget·
Fair Value US$28 5.4% undervalued intrinsic discount

Growing Myopia And Aging Population Will Expand Vision Correction Opportunities

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·
Fair Value US$24.63 7.6% overvalued intrinsic discount

Introduction Of EVO+ Will Open Market Opportunities In 2025

2users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AnalystLowTarget·
Fair Value US$16 65.6% overvalued intrinsic discount

Geopolitical Tensions And Regulatory Pressures Will Depress Margins

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Recent STAA News & Updates

STAAR Surgical: Takeover Offer Comes At A Significant Premium

Aug 05

Getting In Cheap On STAAR Surgical Company (NASDAQ:STAA) Might Be Difficult

Jul 04
Getting In Cheap On STAAR Surgical Company (NASDAQ:STAA) Might Be Difficult

STAAR Surgical Company Key Details

US$224.4m

Revenue

US$63.5m

Cost of Revenue

US$160.9m

Gross Profit

US$256.2m

Other Expenses

-US$95.3m

Earnings

Last Reported Earnings
Jun 27, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
-1.93
Gross Margin
71.70%
Net Profit Margin
-42.45%
Debt/Equity Ratio
0%

STAAR Surgical Company Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Flawless balance sheet with reasonable growth potential.

1 Risk
2 Rewards

About STAA

Founded
1982
Employees
1157
CEO
Stephen Farrell
WebsiteView website
www.staar.com

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) and laser-based procedures, such as LASIK to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

U.S. Market Performance

  • 7 Days: 0.3%
  • 3 Months: 8.5%
  • 1 Year: 17.3%
  • Year to Date: 15.0%
Over the last 7 days, the market has remained flat, with no particular sector making any big moves this week. As for the longer term, the market has risen 17% in the past 12 months. Earnings are forecast to grow by 15% annually. Market details ›